Dr. Luis Marrero has received a $315,000 Phase I Small Business Innovation Research (SBIR) grant from the NIH's National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to explore new treatments for non-compliant arthrofibrosis. As the Principal Investigator, Dr. Marrero is leading a collaboration with NovoMedix to evaluate their innovative, first-in-class small-molecule IL-11 inhibitors as a potential drug therapy for musculoskeletal fibrosis. Successful completion of this phase could make the project eligible for a larger, multi-year Phase II award of around $2 million to potentially support a clinical trial.